Oxford, United Kingdom
Orbit Discovery, founded in 2015 as a spin-out from Oxford University, is crafting a niche in the biotechnology arena with its unique peptide display engine. Focused on delivering peptide-enabled drug discovery solutions, Orbit Discovery concentrates on cell-based targets to provide novel therapeutic leads.
Their technology is pivotal for developing peptide, peptidomimetic, and small molecule therapeutics, as well as bioconjugates. This novel approach, based on leading academic research by Professors Graham Ogg and Terry Rabbitts, aims to advance healthcare innovation by addressing targets in biologically relevant contexts.
Headquartered in the United Kingdom, the company received a £5.58M seed round investment on 20 July 2021. This round saw participation from investors such as Borealis Ventures, Oxford Science Enterprises, Perivoli Innovations, and Kapil Dev Joory. They focus on fostering industry and academia collaborations to broaden the accessibility of their transformative technology.
